During a live event, Ahmad Tarhini, MD, PhD, and participants discussed how to use combination immunotherapy in patients with ...

Ravindra Uppaluri, MD, PhD, discusses findings from the KEYNOTE-689 trial in adult patients with resectable, locally advanced head and neck squamous cell carcinoma.

This week in oncology has been marked by significant strides in targeted therapies, a re-evaluation of established treatment paradigms, and compelling evidence for the impact of lifestyle ...

During a Community Case Forum event, Adil Daud, MD, discussed immunotherapy options for cutaneous squamous cell carcinoma.

During a live event, Matthew Galsky, MD, discussed adjuvant and neoadjuvant treatment approaches for muscle-invasive bladder ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Living in food deserts, clinical trial deserts, and areas with high transportation vulnerability significantly lowers breast ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, John S. Renshaw, MD, and other oncologists discussed various trials of novel regimens for patients with ...

Ravindra Uppaluri, MD, PhD, discusses the background regarding locally advanced head and neck cancer and what the trial design of KEYNOTE-689 entailed.

The FDA approved intravesical mitomycin in non–muscle-invasive bladder cancer as an nonsurgical alternative to transurethral ...

The FDA approved taletrectinib for ROS1-positive NSCLC. The agent shows efficacy for both new and pretreated cases, including ...